GlassScriptPhysician profile
Jackson Reynolds
NPI 1689036048
$7,084.34
in general payments reported to CMS, 2019-2025
52 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.29 · 2021: $352 · 2022: $231 · 2023: $3,668 · 2024: $1,860 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,335 · Education: $89.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,335.10 |
| Education | $89.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,181.47 | 2021-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $501.52 | 2023-2025 | |
| Celgene Corporation | $384.91 | 2022-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $383.61 | 2022-2025 | Erleada, Akeega, Balversa |
| Incyte Corporation | $313.09 | 2020-2025 | Monjuvi, Pemazyre, Jakafi |
| Regeneron Healthcare Solutions, INC. | $285.10 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $234.95 | 2021-2022 | |
| Pfizer INC. | $234.47 | 2023-2024 | |
| Beigene USA, INC. | $206.67 | 2020-2025 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $171.74 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $153.29 | 2023-2025 | |
| Amgen INC. | $130.64 | 2020-2021 | |
| Daiichi Sankyo INC. | $128.45 | 2023-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $126.91 | 2023-2025 | Ninlaro, Iclusig |
| Eisai INC. | $118.09 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $117.17 | 2023-2024 | |
| Seagen INC. | $112.62 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Deciphera Pharmaceuticals INC. | $99.67 | 2023-2025 | Qinlock, Romvimza, Tgct |
| Ipsen Biopharmaceuticals, INC | $93.86 | 2024 | Onivyde, Somatuline Depot |
| Abbvie INC. | $87.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.20 | 2025 | Imfinzi |
| Genentech USA, INC. | $80.24 | 2024-2025 | Polivy, Tecentriq, Itovebi |
| Myriad Genetic Laboratories, INC. | $59.30 | 2024 | Bracanalysis Cdx |
| Pharmacosmos Therapeutics INC. | $59.22 | 2023-2025 | Monoferric, Cosela |
| Array Biopharma INC | $51.29 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Servier Pharmaceuticals LLC | $46.65 | 2024-2025 | |
| Mirati Therapeutics, INC. | $41.76 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $41.09 | 2023-2024 | Ojjaara, Shingrix |
| Stemline Therapeutics INC. | $39.95 | 2023-2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $39.20 | 2023-2024 | Fotivda |
| Karyopharm Therapeutics INC. | $35.40 | 2023-2024 | Xpovio |
| Blueprint Medicines Corporation | $35.29 | 2022-2023 | Ayvakit |
| Adc Therapeutics America, INC. | $34.69 | 2024-2025 | |
| Sobi, INC | $33.63 | 2022 | |
| Taiho Oncology, INC. | $30.58 | 2023 | |
| Emd Serono, INC. | $28.60 | 2023-2024 | Bavencio |
| Astellas Pharma US INC | $27.54 | 2023 | Padcev |
| Lilly USA, LLC | $24.61 | 2020-2024 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $19.35 | 2023 | Imbruvica |
| G1 Therapeutics, INC. | $18.33 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Vivimusta |
| Recordati_rare_diseases_inc. | $17.51 | 2023 | Sylvant |
| Sun Pharmaceutical Industries INC. | $16.72 | 2023 | Yonsa, Odomzo |
| Rigel Pharmaceuticals, INC. | $16.62 | 2022 | |
| Springworks Therapeutics, INC. | $16.31 | 2024 | Ogsiveo |
| Novo Nordisk INC | $16.19 | 2020 | |
| Puma Biotechnology, INC. | $15.25 | 2023 | Nerlynx |
| Genmab U.S., INC. | $14.64 | 2024 | Epkinly |
| Kite Pharma, INC. | $14.38 | 2023 | |
| Beone Medicines USA, INC. | $13.85 | 2025 | Tevimbra |
| Sumitomo Pharma America, INC. | $13.51 | 2024 | Orgovyx |
| Morphosys, US INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.